Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

NCT ID: NCT00296387

Last Updated: 2007-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosuvastatin

Intervention Type DRUG

Atorvastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion,
* Percutaneous coronary intervention (PCI) planned,
* Evidence of coronary artery disease

Exclusion Criteria

* Hypersensitivity to statins
* Any cholesterol lowering medication taken within 1 month prior V1
* Sustained ST-segment elevation on ECG
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AstraZeneca France Medical Director, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Aalst, , Belgium

Site Status

Research Site

Bonheiden, , Belgium

Site Status

Research Site

Bouge, , Belgium

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Charleroi, , Belgium

Site Status

Research Site

Hasselt, , Belgium

Site Status

Research Site

Huy, , Belgium

Site Status

Research Site

La Louvière, , Belgium

Site Status

Research Site

Leuven, , Belgium

Site Status

Research Site

Edmonton, Alberta, Canada

Site Status

Research Site

Vancouver, British Columbia, Canada

Site Status

Research Site

Victoria, British Columbia, Canada

Site Status

Research Site

Winnipeg, Manitoba, Canada

Site Status

Research Site

Saint John, New Brunswick, Canada

Site Status

Research Site

St. John's, Newfoundland and Labrador, Canada

Site Status

Research Site

Halifax, Nova Scotia, Canada

Site Status

Research Site

Kingston, Ontario, Canada

Site Status

Research Site

London, Ontario, Canada

Site Status

Research Site

Scarborough Village, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Laval, Quebec, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Pointe-Claire, Quebec, Canada

Site Status

Research Site

Saint-Charles-Borromée, Quebec, Canada

Site Status

Research Site

Sherbrooke, Quebec, Canada

Site Status

Research Site

Regina, Saskatchewan, Canada

Site Status

Research Site

Tallinn, , Estonia

Site Status

Research Site

Tartu, , Estonia

Site Status

Research Site

Amiens, , France

Site Status

Research Site

Annecy, , France

Site Status

Research Site

Arras, , France

Site Status

Research Site

Avignon, , France

Site Status

Research Site

Boulogne-Billancourt, , France

Site Status

Research Site

Caen, , France

Site Status

Research Site

Cholet, , France

Site Status

Research Site

Créteil, , France

Site Status

Research Site

Dijon, , France

Site Status

Research Site

Eaubonne, , France

Site Status

Research Site

Évecquemont, , France

Site Status

Research Site

Falaise, , France

Site Status

Research Site

La Roche-sur-Yon, , France

Site Status

Research Site

Lagny-sur-Marne, , France

Site Status

Research Site

Le Coudray, , France

Site Status

Research Site

Le Mans, , France

Site Status

Research Site

Lille, , France

Site Status

Research Site

Marseille, , France

Site Status

Research Site

Metz, , France

Site Status

Research Site

Montpellier, , France

Site Status

Research Site

Nevers, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Pau, , France

Site Status

Research Site

Pessac, , France

Site Status

Research Site

Reims, , France

Site Status

Research Site

Rouen, , France

Site Status

Research Site

Saint-Herblain, , France

Site Status

Research Site

Suresnes, , France

Site Status

Research Site

Toulouse, , France

Site Status

Research Site

Tourcoing, , France

Site Status

Research Site

Tours, , France

Site Status

Research Site

Valenciennes, , France

Site Status

Research Site

Vannes, , France

Site Status

Research Site

Villeurbanne, , France

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Balatonfüred, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Pécs, , Hungary

Site Status

Research Site

Zalaegerszeg, , Hungary

Site Status

Research Site

Dublin, , Ireland

Site Status

Research Site

Galway, , Ireland

Site Status

Research Site

Limerick, , Ireland

Site Status

Research Site

Bari, Apulia, Italy

Site Status

Research site

Cosenza, Basilicate, Italy

Site Status

Research Site

Benevento, Campania, Italy

Site Status

Research Site

Mantova, Lombardy, Italy

Site Status

Research Site

Rozzano (Milano), Lombardy, Italy

Site Status

Research Site

Catania, Sicily, Italy

Site Status

Research Site

Pisa, Tuscany, Italy

Site Status

Research Site

Perugia, Umbria, Italy

Site Status

Research Site

Verona, Veneto, Italy

Site Status

Research Site

Bolzano, , Italy

Site Status

Research Site

Napoli, , Italy

Site Status

Research Site

Padua, , Italy

Site Status

Research Site

Roma, , Italy

Site Status

Research Site

Aveiro, , Portugal

Site Status

Research Site

Braga, , Portugal

Site Status

Research Site

Carnaxide, , Portugal

Site Status

Research Site

Faro, , Portugal

Site Status

Research Site

Funchal, , Portugal

Site Status

Research Site

Leiria, , Portugal

Site Status

Research Site

Vila Real, , Portugal

Site Status

Research Site

Zaragoza, Aragon, Spain

Site Status

Research Site

Toledo, Castille-La Mancha, Spain

Site Status

Research Site

Tarragona, Catalonia, Spain

Site Status

Research Site

Fuenlabrada(Madrid), Madrid, Spain

Site Status

Research site

Madrid, Madrid, Spain

Site Status

Research Site

Vigo, Pontevedra, Spain

Site Status

Research Site

Sant Joan d'Alacant, Valencia, Spain

Site Status

Research Site

Seville, , Spain

Site Status

Research Site

BAB Saâdoun Tunis, , Tunisia

Site Status

Research Site

SIDI Daoud Tunis, , Tunisia

Site Status

Research Site

Sousse, , Tunisia

Site Status

Research Site

Tunis, , Tunisia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Canada Estonia France Greece Hungary Ireland Italy Portugal Spain Tunisia

References

Explore related publications, articles, or registry entries linked to this study.

Lablanche JM, Leone A, Merkely B, Morais J, Alonso J, Santini M, Eha J, Demil N, Licour M, Tardif JC; CENTAURUS investigators. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. Arch Cardiovasc Dis. 2010 Mar;103(3):160-9. doi: 10.1016/j.acvd.2010.01.005. Epub 2010 Apr 8.

Reference Type DERIVED
PMID: 20417447 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CENTAURUS

Identifier Type: -

Identifier Source: secondary_id

D3560L00052

Identifier Type: -

Identifier Source: org_study_id